Astellas Pharma Inc.

05/06/2021 | Press release | Distributed by Public on 05/05/2021 19:45

Astellas’ XTANDI (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer